Shenzhen Chipscreen Biosciences Ltd.

12 articles about Shenzhen Chipscreen Biosciences Ltd.

• Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

  11/2/2023

  Shenzhen Chipscreen Biosciences Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration through its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd.

• Akeso Announced Collaboration With Chipscreen Biosciences To Initiated A Clinical Trial Of PD-1/CTLA-4 Bi-Specific Antibody In Combination With Chiauranib For PD-(L)1 Pretreated ES-SCLC

  3/2/2022

  Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-1 inhibitor treatment regimen for extensive stage small cell lung cancer.

• Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

  6/24/2021

  Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International, announced the regulatory approval for Tucidinostat monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma by the Japanese Pharmaceuticals and Medical Devices Agency.

• Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

  4/16/2021

  Shenzhen Chipscreen Biosciences announces that it has received Investigational New Drug clearance from the US Food and Drug Administration to proceed with a Phase 1b/2 clinical trial of Chiauranib/CS2164, a potential treatment for multiple oncological indications including Small Cell Lung Cancer, Ovarian Cancer, Liver Cancer, and Breast Cancer, etc.

• Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.

  1/11/2021

  On January 8, 2021, Shenzhen Chipscreen Biosciences Co., Ltd. submitted its pivotal phase III clinical trial application of national class I innovative drug Chiauranib to NMPA, for the treatment of Small Cell Lung Cancer as a single agent for the patients after 2nd-line systemic chemotherapy and recurrence afterwards.

• Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"

  1/5/2021

  Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer with disease progression or recurrence after two lines of prior systematic chemotherapy.

• Chipscreen and HISUN reach a strategic cooperation

  12/16/2020

  On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. announced that they have reached a strategic cooperation.

• Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

  3/24/2020

  Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company's application for Investigational New Drug of CS12192 has been accepted by Center for Drug Evaluation, National Medical Products Administration of China.

• National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

  11/29/2019

  On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company's lead innovative product Epidaza®, an oral subtype-selective histone deacetylase inhibitor, previously approved for recurrent and refractory peripheral T cell lymphoma in China, has received approval for marketing application in its second indication from NMPA.

• Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients

  2/18/2019

  Innovent Biologics, Inc. announced the signing of a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd.

• Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint

  5/29/2018

  Shenzhen Chipscreen Biosciences Co., Ltd. has been informed that the company's lead innovative product Epidaza® in combination with exemestane reached primary endpoint (progression-free survival) in a pivotal phase III clinical trial.

• GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule From Shenzhen Chipscreen Biosciences Ltd.

  10/10/2013